Fraccarollo, Daniela
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. [electronic resource]
- Basic research in cardiology Jul 2014
- 421 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
ISSN: 1435-1803
Standard No.: 10.1007/s00395-014-0421-1 doi
Subjects--Topical Terms: Angiotensin-Converting Enzyme Inhibitors--pharmacology Animals Cardiotonic Agents--pharmacology Cell Communication Cells, Cultured Disease Models, Animal Drug Therapy, Combination Enzyme Activation Enzyme Activators--pharmacology Extracellular Matrix--metabolism Fibrosis Guanylate Cyclase--metabolism Heart Failure--drug therapy Hemodynamics--drug effects Humans Male Mice Mitochondria, Heart--drug effects Myocardial Contraction--drug effects Myocardial Infarction--complications Myocytes, Cardiac--drug effects Myofibroblasts--drug effects Nitric Oxide--metabolism Nitric Oxide Synthase Type III--metabolism Oxidative Stress--drug effects Ramipril--pharmacology Rats, Wistar Receptors, Cytoplasmic and Nuclear--metabolism Soluble Guanylyl Cyclase Sulfonamides--pharmacology Superoxides--metabolism Time Factors Ventricular Function, Left--drug effects Ventricular Remodeling--drug effects ortho-Aminobenzoates--pharmacology